The TIGD5 gene located in 8q24 and frequently amplified in ovarian cancers is a tumor suppressor
- PMID: 36054307
- DOI: 10.1111/gtc.12980
The TIGD5 gene located in 8q24 and frequently amplified in ovarian cancers is a tumor suppressor
Abstract
Ovarian cancer (OC) is the fifth most common cancer of female cancer death and leading cause of lethal gynecological cancers. High-grade serous ovarian carcinoma (HGSOC) is an aggressive malignancy that is rapidly fatal. Many cases of OC show amplification of the 8q24 chromosomal region, which contains the well-known oncogene MYC. Although MYC amplification is more frequently observed in OCs than in other tumor types, due to the large size of the 8q24 amplicon, the functions of the vast majority of the genes it contains are still unknown. The TIGD5 gene is located at 8q24.3 and encodes a nuclear protein with a DNA-binding motif, but its precise role is obscure. We show here that TIGD5 often co-amplifies with MYC in OCs, and that OC patients with high TIGD5 mRNA expression have a poor prognosis. However, we also found that TIGD5 overexpression in ovarian cancer cell lines unexpectedly suppressed their growth, adhesion, and invasion in vitro, and also reduced tumor growth in xenografted nude mice in vivo. Thus, our work suggests that TIGD5 may in fact operate as a tumor suppressor in OCs rather than as an oncogene.
Keywords: 8q24; MYC; TIGD5; ovarian cancer; tumor suppressor.
© 2022 Molecular Biology Society of Japan and John Wiley & Sons Australia, Ltd.
Similar articles
-
Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model.Anticancer Res. 2024 May;44(5):1817-1827. doi: 10.21873/anticanres.16983. Anticancer Res. 2024. PMID: 38677725
-
Amplification of C-MYC as the origin of the homogeneous staining region in ovarian carcinoma detected by micro-FISH.Cancer Genet Cytogenet. 1999 Oct 15;114(2):136-43. doi: 10.1016/s0165-4608(99)00064-3. Cancer Genet Cytogenet. 1999. PMID: 10549271
-
In vivo tumor growth of high-grade serous ovarian cancer cell lines.Gynecol Oncol. 2015 Aug;138(2):372-7. doi: 10.1016/j.ygyno.2015.05.040. Epub 2015 Jun 5. Gynecol Oncol. 2015. PMID: 26050922 Free PMC article.
-
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.J Ovarian Res. 2021 Nov 4;14(1):149. doi: 10.1186/s13048-021-00899-6. J Ovarian Res. 2021. PMID: 34736492 Free PMC article.
-
Human ovarian cancer of the surface epithelium.Biochem Pharmacol. 1997 Sep 1;54(5):541-4. doi: 10.1016/s0006-2952(97)00061-0. Biochem Pharmacol. 1997. PMID: 9337069 Review.
Cited by
-
Quantitative mapping of proteasome interactomes and substrates using ProteasomeID.Elife. 2024 Sep 4;13:RP93256. doi: 10.7554/eLife.93256. Elife. 2024. PMID: 39230574 Free PMC article.
References
REFERENCES
-
- Abugessaisa, I., & Kasukawa, T. (2021). Practical guide to life science databases. Springer.
-
- Baker, V. V., Borst, M. P., Dixon, D., Hatch, K. D., Shingleton, H. M., & Miller, D. (1990). C-myc amplification in ovarian cancer. Gynecologic Oncology, 38, 340-342.
-
- Bowtell, D. D., Bohm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Jr., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., Brenton, J. D., Chiappinelli, K. B., Martins, F. C., Coukos, G., Drapkin, R., Edmondson, R., Fotopoulou, C., Gabra, H., Galon, J., … Pharoah, P. (2015). Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer, 15, 668-679.
-
- Breyer, J. P., Dorset, D. C., Clark, T. A., Bradley, K. M., Wahlfors, T. A., McReynolds, K. M., Maynard, W. H., Chang, S. S., Cookson, M. S., Smith, J. A., Schleutker, J., Dupont, W. D., & Smith, J. R. (2014). An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. American Journal of Human Genetics, 94, 395-404.
-
- Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609-615.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
